Pharmacovigilance Program impact on notifications of adverse reactions to antineoplastic drug in a university hospital
DOI:
https://doi.org/10.30968/rbfhss.2024.152.1118Abstract
Objective: To evaluate the Pharmacovigilance Program impact on notifications of adverse reactions to antineoplastic drugs (ADR) in a university hospital. Methods: Cross-sectional, descriptive and retrospective study, carried out by surveying spontaneous notifications of suspected antineoplastic ADR arising from hospitalization and chemotherapy outpatient clinics and sent to the Pharmacovigilance Program of the Clinical Pharmacy section, of the Pharmacy Service of a university hospital in Porto Alegre. This work was approved by the Research Ethics Committee of that institution under number 2019-0408. Results: In 2020, the Pharmacovigilance Program received 71 notifications involving antineoplastic ADR, representing 59.7% of the total notifications received. In 2021, ADR notifications involving antineoplastics represented 47% (n=49) of notifications received. In 2022, the notifications received had an even greater reduction, with 24, representing 37% of the total notifications received in the year. In the year 2023, however, it was possible to observe an increase both in the number of spontaneous reports suspected of total ADR (n=95), as well as in the number of antineoplastics (n=45) and, consequently, in the percentage of spontaneous reports suspected of ADRs. antineoplastic ADR (47%). Conclusion: The notifications monitoring involving antineoplastics by Pharmacovigilance demonstrated the need to formulate a strategy to return to the notifier with educational objectives in conjunction with professionals from the chemotherapy outpatient clinic and the care area involved in the notifications.
Downloads
References
Agência Nacional de Vigilância Sanitária. Boletim de Farmacovigilância: Farmacovigilância ativa. Available in: https://antigo.anvisa.gov.br/documents/33868/2894786/Boletim+de+Farmacovigil%C3%A2ncia+n%C2%BA+10/edccfdd-4-0645-418a-92d5-b328df8639e9?version=1.2. Acessed on: January 30, 2024.
Organização Pan-Americana da Saúde. Boas práticas de farmacovigilância para as Américas. Available in: https://www3.paho.org/hq/dmdocuments/2011/Red-PARF-5-Port.pdf. Acessed on: January 30, 2024.
Agência Nacional de Vigilância Sanitária. Sociedade Brasileira de Farmacêuticos em Oncologia. Guia para Notificações de Reações Adversas em Oncologia. 2. ed. São Paulo, 2011.
Mastroiann PC, Varallo FR. Farmacovigilância para promoção do uso correto de medicamentos. Porto Alegre: Artmed; 2013.
Institute For Safe Medication Practices - Brasil (ISMP Brasil). Boletim eletrônico: segurança do paciente. Available in: https://www.ismp-brasil.org/site/wp-content/uploads/2015/07/V3N3.pdf. Acessed on: January 30, 2024.
Diemen TV, Algayer VCS, Wayhs CAY. Perfil das notificações de reações adversas a medicamentos antineoplásicos encaminhadas ao programa de farmacovigilância de um hospital universitário em Porto Alegre. Revista Científica Internacional Rev SALUS. 2023;5(3):33-40. DOI:10.51126/revsalus.v5i3.529.
Yamashita SR, Noblat LA, Machado IC. A Pharmacovigilance data restructuring proposal of a teaching hospital. Rev Bras Farm Hosp Serv Saude. 2019;10(2):0409. DOI: 10.30968/rbfhss.2019.102.0409.
Jovito BL, Oliveira AC, Mourão CA, et al. Cross-sectional study of active pharmacovigilance in a private hospital of Distrito Federal during the first semester of 2021. Rev Bras Farm Hosp Serv Saude. 2021;12(4):0691. DOI: 10.30968/rbfhss.2021.124.0691.
Martins TL, Pinto AR, Pires JMD, et al. Reação adversa induzida por capecitabina: a importância da farmacovigilância. Rev Bras Farm Hosp Serv Saúde. 2013;4(3):24-26.
Baldo P, Fornasier G, Ciolfi L, et al. Pharmacovigilance in oncology. Int J Clin Pharm. 2018;40(4):832-841. DOI: 10.1007/s11096-018-0706-9.
Silveira GB, Santos CO, Camargo AL. Medication safety incidents: characterization of voluntary reports in an oncology hospital in Porto Alegre. Rev Bras Farm Hosp Serv Saude. 2022;13(1):0730. DOI: 10.30968/rbfhss.2022.131.0730.
Duarte ML, Batista LM, Albuquerque PMS. Notificações de farmacovigilância em um hospital oncológico sentinela da paraíba. Rev Bras Farm Hosp Serv Saúde. 2014;5(1)7-11.
Romano-Lieber NS, Teixeira JJV, Farhat FCLG, et al. Revisão dos estudos de intervenção do farmacêutico no uso de medicamentos por pacientes idosos. Caderno de Saúde Pública. 2002;18(6):1499-1507. DOI:10.1590/S0102-311X2002000600002.
Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-270. DOI:10.1001/jama.282.3.267.
Agrizzi AL, Pereira LC, Figueira PHM. Metodologia de busca ativa para detecção de reações adversas a medicamentos em pacientes oncológicos. Rev Bras Farm Hosp Serv Saude. 2013;4(1):6-11.
Almeida ED, Nascimento GS, Antunes LML, Kwong WLS, Oliveira CMS. Subnotificação de reações adversas a medicamentos: Uma barreira na Farmacovigilância. Revista Ibero-Americana de Humanidades, Ciência e Educação. 2022;8(11):383-90.
Lavan AH, O’Mahony D, Buckley M, O’Mahony D, Gallagher P. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability.2019;24(9)e968-77.
Silva SPC, Jesus M, Roque F, Herdeiro MT, Souza RC, Duarte AP, Morgado M. Active Pharmacovigilance Study: A Follow-Up Model of Oral Anti-Cancer Drugs under Additional Monitoring. Current Oncology 2023; 30(4):4139-42. DOI: 10.3390/curroncol30040315.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
Rawat BP, Jagannatha A, Liu F, Yu H. Inferring ADR causality by predicting the Naranjo Score from Clinical Notes. AMIA Annual Symposium Proceedings Archive. 2020;2020:1041-9.
Vaseghi G, Abed A, Jafari E, Eslami N, Eshraghi A. Assessment of Adverse Drug Reaction Due to Cancer Chemotherapy in a Teaching Oncology Hospital In Isfahan, Central of Iran. Reviews on recent clinical trials. 2016;11(3):266-72.
Shrestha S, Sharma S, Bhasima R, Kunwor P, AdhiKari B, Sapkota B. Impact of an educational intervention on pharmacovigilance Knowledge and attitudes among health professionals in a Nepal cancer hospital. BMC Medical Education. 2020;20(1):179-89. DOI: 10.1186/s12909-020-02084-7.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
